ArticleThe American journal of case reports2025
Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia Accompanied with Very Severe Thrombocytopenia.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal-dominant disorder characterized by recurrent epistaxis and gastrointestinal bleeding (GIB). To our knowledge, the management of GIB in HHT patients accompanied with very severe thrombocytopenia has not been previously reported. CASE REPORT A 66-year-old woman with HHT who experienced recurrent epistaxis for over 5 years was admitted to the hospital due to intermittent hematemesis and melena for 2 weeks. Following admission, her platelet count dropped significantly to 1×10⁹/L. Following supportive treatments, a gastroscopy was performed when the platelet count reached 23×10⁹/L. The gastroscopy revealed over 50 angioectatic spots with active bleeding. These spots were treated by argon plasma coagulation and the bleeding was stopped. She had a favorable prognosis following discharge. CONCLUSIONS This case highlights the rare coexistence of HHT, GIB, and very severe thrombocytopenia, offering insights into proton pump inhibitor (PPI)-induced thrombocytopenia. Immediate discontinuation of the involved PPI is advised. Platelet transfusion (<20×109/L) combined with recombinant human interleukin-11 is recommended for patients at risk of GIB. If PPI therapy is necessary, it is a novel and effective strategy to switch to another PPI with a different chemical structure, accompanied by close platelet monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.